You are here

Roche

After $250M Roche buyout, a startup plans a second strike with fresh funding

BioPharma Dive

Tue, 11/15/22 - 10:36 am

Bonum Therapeutics

Good Therapeutics

Trial failures end latest hope for Roche’s Alzheimer’s drug

BioPharma Dive

Mon, 11/14/22 - 10:57 am

Alzheimer's disease

clinical trials

As Roche prepares to take a kidney disease drug into PhIII, Ionis fleshes out the data

Endpoints

Mon, 11/7/22 - 05:24 pm

Ionis Pharmaceuticals

Roche introduces the navify brand for its digital health solutions at HLTH 2022

BioSpace

Fri, 11/4/22 - 11:05 am

Roche’s Ocrevus Shines in Relapsing-Remitting MS, Safety Studies

BioSpace

Thu, 11/3/22 - 07:28 pm

Relapsing Remitting Multiple Sclerosis

Roche's Vabysmo lands clinical counterpunch in ophthalmology brawl with Eylea

Fierce Pharma

Thu, 10/27/22 - 11:02 am

bispecific antibodies

AstraZeneca beats Roche twice in a day

EP Vantage

Wed, 10/26/22 - 10:20 am

Roche issues voluntary recall for Susvimo over manufacturing issue

Endpoints

Sun, 10/23/22 - 06:57 pm

ocular implants

wet age-related macular degeneration

product recalls

Roche, Hookipa Pharma agree $25 million deal for arenaviral immunotherapy

Pharmaphorum

Fri, 10/21/22 - 10:18 am

Roche CEO Cautious on Alzheimer’s Trial Despite Eisai’s Success

Bloomberg

Wed, 10/19/22 - 10:35 am

Alzheimer's disease

Roche Scraps Mid-Phase Programs in Hepatitis B, Geographic Atrophy

BioSpace

Tue, 10/18/22 - 10:01 pm

geographic atrophy

Roche Q3 results show steep fall-off in COVID product sales

Pharmaphorum

Tue, 10/18/22 - 10:50 am

The gloom deepens for biopharma stocks

EP Vantage

Mon, 10/10/22 - 06:54 pm

biopharma stocks

CRISPR Therapeutics

Intellia Therapeutics

Sarepta Therapeutics

Bayer, Hua Medicine snag first-in-class nod in China for Roche castoff diabetes drug

Fierce Pharma

Mon, 10/10/22 - 10:57 am

Roche nets FDA approval for HER2-low breast cancer test paired with AstraZeneca-Daiichi's Enhertu

Fierce Biotech

Wed, 10/5/22 - 07:07 pm

HER2-low breast cancer

ICER Deems Hemophilia Gene Therapies Worth the $2.5M Price Tag

BioSpace

Thu, 09/15/22 - 10:14 am

AstraZeneca, Eli Lilly and Roche among pharmaceutical companies upgraded for high returns on R&D investments, analysts say

Morningstar

Wed, 09/14/22 - 09:31 am

ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?

Fierce Pharma

Mon, 09/12/22 - 10:57 am

Bristol Myers Squibb

ESMO 2022 – Keytruda secures a renal cancer monopoly

EP Vantage

Thu, 09/8/22 - 12:03 am

Bristol Myers Squibb

Pages